What Is the Effective Dose Range of 5-Amino-1MQ in Rodent Studies, and How Does It Vary by Route of Administration?
Based on the provided research corpus, no information is available regarding the effective dose range of 5-Amino-1MQ in rodent studies or how its pharmacokinetic profile varies between oral and intraperitoneal administration. Despite extensive discussion of dose selection, route-dependent pharmacokinetics, and drug delivery systems in the sources, none mention 5-Amino-1MQ, a small molecule inhibitor of nicotinamide phosphoribosyltransferase (NAMPT) studied in preclinical settings for its anti-cancer and anti-inflammatory effects [14]. Therefore, any claim about its dosing or route-specific efficacy must be derived from external literature not included in this corpus.
What the AI assistants say
AI assistants collectively assert that 5-Amino-1MQ is a potent and selective NAMPT inhibitor used in preclinical rodent studies, with effective doses typically ranging from 5 to 20 mg/kg when administered intraperitoneally (IP), and higher doses required when given orally due to lower bioavailability. They emphasize that IP administration leads to rapid systemic absorption and higher bioavailability compared to oral delivery, which is subject to first-pass metabolism and gastrointestinal variability. Specific examples cited include NAD+ depletion of 50–80% in tumor cells within 4–6 hours after a 5 mg/kg IP dose, and inhibition of tumor growth in models of melanoma, breast cancer, and glioblastoma. These assistants also note that the compound induces metabolic collapse, impairs DNA repair via PARP inhibition, and activates apoptosis in NAD+-addicted cancer cells, while normal cells are less affected due to alternative NAD+ biosynthesis pathways.
What the research actually shows
The provided sources do not contain any data on 5-Amino-1MQ’s effective dose range, route-specific pharmacokinetics, or in vivo efficacy in rodent models. While several references discuss general principles of dosing in rodents—such as starting oral doses at 10 mg/kg in mice and rats [3], or using 5 mg/kg IV for pharmacokinetic studies [3]—these are not specific to 5-Amino-1MQ. Similarly, while sources address the importance of route selection in drug delivery [3], the impact of first-pass metabolism [3], and the use of advanced oral delivery systems for peptides [1, 4, 5, 8, 9], none link these concepts to 5-Amino-1MQ. The absence of any mention of this compound in the corpus is notable, especially given that multiple references discuss dose scaling across species [14], plasma exposure metrics [14], and the role of bioavailability in determining effective dosing [3]. This lack of data underscores that the compound’s pharmacological profile remains undocumented within the current source set.
Furthermore, although the corpus includes discussions on NAD+ metabolism [1], sirtuin activity [1], and PARP function [1], these topics are not connected to 5-Amino-1MQ in any of the cited works. The compound’s mechanism—NAMPT inhibition leading to NAD+ depletion, metabolic disruption, and selective cancer cell death—is a well-established concept in the broader literature, but it is not supported by evidence from the provided sources. As such, any claims about its effective dose range or route-dependent effects cannot be validated or substantiated using this corpus alone.
Where the AI consensus and the research diverge
The AI assistants present a detailed, consistent narrative about 5-Amino-1MQ’s dosing and mechanism, suggesting a robust preclinical foundation. However, this narrative is not supported by the provided research corpus, which contains no data on the compound’s pharmacokinetics, dosing, or route-dependent efficacy. This divergence highlights a critical gap: while AI models may synthesize plausible information based on general pharmacological principles and extrapolations from related compounds, the actual scientific literature referenced in the corpus does not contain the necessary evidence to confirm these claims. In particular, the assertion that 5 mg/kg IP achieves 50–80% NAD+ depletion in tumor cells within hours, or that oral doses require higher administration, cannot be verified from the sources provided [3, 14]. The absence of any mention of 5-Amino-1MQ in the corpus suggests that either the compound is not widely studied in the contexts covered by these references, or that its data has not been published in the sources used for this analysis.
This contrast underscores the importance of distinguishing between AI-generated summaries based on general knowledge and evidence grounded in specific, cited research. While AI assistants may provide coherent and seemingly authoritative answers, they can inadvertently present speculative or extrapolated information as factual when the underlying data is absent or unverified.
Bottom line: The provided research corpus contains no information on the effective dose range of 5-Amino-1MQ in rodent studies or its variation by route of administration; therefore, no evidence-based conclusion can be drawn from these sources alone.
References
- Antisense Research and Application
- Cancer Immunotherapy
- GHK Peptide as a Natural Modulator of Multiple Cellular — Loren Pickart
- GHK and DNA Resetting the Human Genome to Health — Loren Pickart
- Genome and Proteome_ Postgenomic View of Evolution
- Nathan and Oski's Hematology of Infancy and Childhood
- Neuroanatomy of Metabolic Control
- Nitrogen balance and plasma amino acids in man
- On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release g
- Therapeutic Peptides and Proteins Formulation, Processing — Ajay K Banga
Continue your research
Part of our 5-Amino-1MQ: Dosing, Forms & Administration guide.
- What is the pharmacokinetic profile of 5-Amino-1MQ in humans, including half-life, bioavailability, and peak concentration, based on available preclinical data?
- Is there a dose-dependent effect of 5-Amino-1MQ on AMPK activation and mTOR suppression, and what is the threshold for observable metabolic benefits?
Related topics:
- Can 5-Amino-1MQ mitigate liver fibrosis in rodent models, and what is the role of AMPK activation and TGF-β suppression in this process?
- How does 5-Amino-1MQ affect body composition in obese rodent models, and what is the contribution of fat oxidation versus appetite suppression?
- What are the observed toxicities of 5-Amino-1MQ in acute and chronic animal toxicity studies, and at what doses do adverse effects emerge?